Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease
A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levo...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 2007-01, Vol.30 (1), p.18-24 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 24 |
|---|---|
| container_issue | 1 |
| container_start_page | 18 |
| container_title | Clinical neuropharmacology |
| container_volume | 30 |
| creator | Stocchi, Fabrizio Fabbri, Laura Vecsei, Laszlo Krygowska-Wajs, Anna Monici Preti, Piero Alessandro Ruggieri, Stefano A |
| description | A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levodopa/carbidopa (LD/CD) in 74 fluctuating Parkinson disease patients. The first afternoon, LD/CD tablet was substituted with an equimolar dose of CHF 1512. The study lasted 4 weeks and was followed by an 8-week (optional) open phase. The primary efficacy variable was latency to "on." Patients randomized to receive CHF 1512 had a significative shorter latency to "on" than those randomized to LD/CD and a similar "on" duration. The safety profile of CHF 1512 was also comparable with LD/CD. |
| doi_str_mv | 10.1097/01.WNF.0000236762.77913.C6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68967427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68967427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-4347a12dc77540af5f38340b508000e1c3f7db100c5a57016eb322d93053910c3</originalsourceid><addsrcrecordid>eNqFkc1O3TAQRr1oBRT6CpXVRdUuEvwXO2FXRb2AhIAFqEvLccbIba4d7ASJJ-hr1xeuxJLZjKU531ijg9BXSmpKOnVKaP37elOTUoxLJVmtVEd53csP6IhwyapGSnGIPuX8pzBtJ7oDdEgVU6yT8gj96ycfvDUTBudKt884Omxw9uFhAmzcAinEGPAYM-xGBYP0BNlCWPAET3GMs6msSYPfvfCcYDbJLL5kvvcXG0wbyn5gH7CbVrusZRIe8K1Jf33Iu70-g8lwgj46M2X4vO_H6H7z666_qK5uzi_7n1eV5aJdKsGFMpSNVqlGEOMax1suyNCQtlwH1HKnxoESYhvTKEIlDJyxseOk4R0llh-jb6975xQfV8iL3vpyyzSZAHHNWradVIKpd0FGRFtKFPDsFbQp5pzA6Tn5rUnPmhK9c6QJ1cWRfnOkXxzpXpbwl_0v67CF8S26F8T_A8fzj7U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20488884</pqid></control><display><type>article</type><title>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Stocchi, Fabrizio ; Fabbri, Laura ; Vecsei, Laszlo ; Krygowska-Wajs, Anna ; Monici Preti, Piero Alessandro ; Ruggieri, Stefano A</creator><creatorcontrib>Stocchi, Fabrizio ; Fabbri, Laura ; Vecsei, Laszlo ; Krygowska-Wajs, Anna ; Monici Preti, Piero Alessandro ; Ruggieri, Stefano A</creatorcontrib><description>A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levodopa/carbidopa (LD/CD) in 74 fluctuating Parkinson disease patients. The first afternoon, LD/CD tablet was substituted with an equimolar dose of CHF 1512. The study lasted 4 weeks and was followed by an 8-week (optional) open phase. The primary efficacy variable was latency to "on." Patients randomized to receive CHF 1512 had a significative shorter latency to "on" than those randomized to LD/CD and a similar "on" duration. The safety profile of CHF 1512 was also comparable with LD/CD.</description><identifier>ISSN: 0362-5664</identifier><identifier>DOI: 10.1097/01.WNF.0000236762.77913.C6</identifier><identifier>PMID: 17272966</identifier><language>eng</language><publisher>United States</publisher><subject>Activities of Daily Living ; Aged ; Antiparkinson Agents ; Carbidopa - therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Drug Combinations ; Female ; Humans ; Levodopa - analogs & derivatives ; Levodopa - therapeutic use ; Male ; Motor Activity - drug effects ; Motor Skills Disorders - etiology ; Motor Skills Disorders - prevention & control ; Nausea - chemically induced ; Parkinson Disease - complications ; Parkinson Disease - drug therapy</subject><ispartof>Clinical neuropharmacology, 2007-01, Vol.30 (1), p.18-24</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-4347a12dc77540af5f38340b508000e1c3f7db100c5a57016eb322d93053910c3</citedby><cites>FETCH-LOGICAL-c348t-4347a12dc77540af5f38340b508000e1c3f7db100c5a57016eb322d93053910c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17272966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stocchi, Fabrizio</creatorcontrib><creatorcontrib>Fabbri, Laura</creatorcontrib><creatorcontrib>Vecsei, Laszlo</creatorcontrib><creatorcontrib>Krygowska-Wajs, Anna</creatorcontrib><creatorcontrib>Monici Preti, Piero Alessandro</creatorcontrib><creatorcontrib>Ruggieri, Stefano A</creatorcontrib><title>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levodopa/carbidopa (LD/CD) in 74 fluctuating Parkinson disease patients. The first afternoon, LD/CD tablet was substituted with an equimolar dose of CHF 1512. The study lasted 4 weeks and was followed by an 8-week (optional) open phase. The primary efficacy variable was latency to "on." Patients randomized to receive CHF 1512 had a significative shorter latency to "on" than those randomized to LD/CD and a similar "on" duration. The safety profile of CHF 1512 was also comparable with LD/CD.</description><subject>Activities of Daily Living</subject><subject>Aged</subject><subject>Antiparkinson Agents</subject><subject>Carbidopa - therapeutic use</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Humans</subject><subject>Levodopa - analogs & derivatives</subject><subject>Levodopa - therapeutic use</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Motor Skills Disorders - etiology</subject><subject>Motor Skills Disorders - prevention & control</subject><subject>Nausea - chemically induced</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - drug therapy</subject><issn>0362-5664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1O3TAQRr1oBRT6CpXVRdUuEvwXO2FXRb2AhIAFqEvLccbIba4d7ASJJ-hr1xeuxJLZjKU531ijg9BXSmpKOnVKaP37elOTUoxLJVmtVEd53csP6IhwyapGSnGIPuX8pzBtJ7oDdEgVU6yT8gj96ycfvDUTBudKt884Omxw9uFhAmzcAinEGPAYM-xGBYP0BNlCWPAET3GMs6msSYPfvfCcYDbJLL5kvvcXG0wbyn5gH7CbVrusZRIe8K1Jf33Iu70-g8lwgj46M2X4vO_H6H7z666_qK5uzi_7n1eV5aJdKsGFMpSNVqlGEOMax1suyNCQtlwH1HKnxoESYhvTKEIlDJyxseOk4R0llh-jb6975xQfV8iL3vpyyzSZAHHNWradVIKpd0FGRFtKFPDsFbQp5pzA6Tn5rUnPmhK9c6QJ1cWRfnOkXxzpXpbwl_0v67CF8S26F8T_A8fzj7U</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Stocchi, Fabrizio</creator><creator>Fabbri, Laura</creator><creator>Vecsei, Laszlo</creator><creator>Krygowska-Wajs, Anna</creator><creator>Monici Preti, Piero Alessandro</creator><creator>Ruggieri, Stefano A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</title><author>Stocchi, Fabrizio ; Fabbri, Laura ; Vecsei, Laszlo ; Krygowska-Wajs, Anna ; Monici Preti, Piero Alessandro ; Ruggieri, Stefano A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-4347a12dc77540af5f38340b508000e1c3f7db100c5a57016eb322d93053910c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Activities of Daily Living</topic><topic>Aged</topic><topic>Antiparkinson Agents</topic><topic>Carbidopa - therapeutic use</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Humans</topic><topic>Levodopa - analogs & derivatives</topic><topic>Levodopa - therapeutic use</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Motor Skills Disorders - etiology</topic><topic>Motor Skills Disorders - prevention & control</topic><topic>Nausea - chemically induced</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stocchi, Fabrizio</creatorcontrib><creatorcontrib>Fabbri, Laura</creatorcontrib><creatorcontrib>Vecsei, Laszlo</creatorcontrib><creatorcontrib>Krygowska-Wajs, Anna</creatorcontrib><creatorcontrib>Monici Preti, Piero Alessandro</creatorcontrib><creatorcontrib>Ruggieri, Stefano A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stocchi, Fabrizio</au><au>Fabbri, Laura</au><au>Vecsei, Laszlo</au><au>Krygowska-Wajs, Anna</au><au>Monici Preti, Piero Alessandro</au><au>Ruggieri, Stefano A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>30</volume><issue>1</issue><spage>18</spage><epage>24</epage><pages>18-24</pages><issn>0362-5664</issn><abstract>A possible cause of motor fluctuations in patients with Parkinson disease is the erratic drug absorption. In a randomized double-blind double-dummy study of melevodopa (levodopa methyl ester), a highly soluble levodopa pro-drug plus carbidopa (CHF 1512) was compared to a standard formulation of levodopa/carbidopa (LD/CD) in 74 fluctuating Parkinson disease patients. The first afternoon, LD/CD tablet was substituted with an equimolar dose of CHF 1512. The study lasted 4 weeks and was followed by an 8-week (optional) open phase. The primary efficacy variable was latency to "on." Patients randomized to receive CHF 1512 had a significative shorter latency to "on" than those randomized to LD/CD and a similar "on" duration. The safety profile of CHF 1512 was also comparable with LD/CD.</abstract><cop>United States</cop><pmid>17272966</pmid><doi>10.1097/01.WNF.0000236762.77913.C6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 2007-01, Vol.30 (1), p.18-24 |
| issn | 0362-5664 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68967427 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Activities of Daily Living Aged Antiparkinson Agents Carbidopa - therapeutic use Double-Blind Method Drug Administration Schedule Drug Combinations Female Humans Levodopa - analogs & derivatives Levodopa - therapeutic use Male Motor Activity - drug effects Motor Skills Disorders - etiology Motor Skills Disorders - prevention & control Nausea - chemically induced Parkinson Disease - complications Parkinson Disease - drug therapy |
| title | Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A43%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20efficacy%20of%20a%20single%20afternoon%20dose%20of%20effervescent%20levodopa-carbidopa%20preparation%20(CHF%201512)%20in%20fluctuating%20Parkinson%20disease&rft.jtitle=Clinical%20neuropharmacology&rft.au=Stocchi,%20Fabrizio&rft.date=2007-01-01&rft.volume=30&rft.issue=1&rft.spage=18&rft.epage=24&rft.pages=18-24&rft.issn=0362-5664&rft_id=info:doi/10.1097/01.WNF.0000236762.77913.C6&rft_dat=%3Cproquest_cross%3E68967427%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20488884&rft_id=info:pmid/17272966&rfr_iscdi=true |